{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:37:13Z","timestamp":1760236633835,"version":"build-2065373602"},"reference-count":94,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The Coronavirus Disease 2019 (COVID-19) pandemic, a global public health emergency, has changed dermatology practice and daily routine in just under two years. Much has been written in the literature about COVID-19-associated skin manifestations. Nevertheless, much less has been written regarding skin manifestations in patients affected by severe immune-mediated skin diseases, e.g., psoriasis and hidradenitis suppurativa, undergoing biological treatment during the COVID-19 outbreak. Thus, the aim of this article is to provide the reader with an overview of the cutaneous manifestations during the COVID-19 pandemic in this subset of patients.<\/jats:p>","DOI":"10.3390\/jcm10245841","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T01:20:41Z","timestamp":1639444841000},"page":"5841","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-7847","authenticated-orcid":false,"given":"Elia","family":"Rosi","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Thais","family":"Fastame","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Di Cesare","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmarco","family":"Silvi","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-2045","authenticated-orcid":false,"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000512932","article-title":"Skin manifestations associated with COVID-19: Current knowledge and future perspectives","volume":"237","author":"Genovese","year":"2020","journal-title":"Dermatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e13733","DOI":"10.1111\/dth.13986","article-title":"Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review","volume":"33","author":"Seirafianpour","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e14504","DOI":"10.1111\/dth.14504","article-title":"Emerging role of anti-IL23 in the treatment of psoriasis: When humanized is very promising","volume":"33","author":"Dattola","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Amoruso, G., Nistic\u00f2, S., Iannone, L., Russo, E., Rago, G., Patruno, C., and Bennardo, L. (2021). Ixekizumab may improve renal function in psoriasis. Healthcare, 9.","DOI":"10.3390\/healthcare9050543"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2\u2014Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments","volume":"84","author":"Gelfand","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/jocd.14104","article-title":"How does COVID-19 impact psoriasis practice, prescription patterns, and healthcare delivery for psoriasis patients? A cross-sectional survey study","volume":"20","author":"Abdelnaby","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1080\/09546634.2020.1764904","article-title":"A challenging case of psoriasis flare-up after COVID-19 infection","volume":"31","author":"Nasiri","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e13383","DOI":"10.1111\/dth.13383","article-title":"A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?","volume":"33","author":"Kutlu","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e13632","DOI":"10.1111\/dth.13632","article-title":"Covid-19 and exacerbation of psoriasis","volume":"33","author":"Ozaras","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ghalamkarpour, F., Pourani, M.R., Abdollahimajd, F., and Zargari, O. (2020). A case of severe psoriatic erythroderma with COVID-19. J. Dermatol. Treat., 1\u20133.","DOI":"10.1080\/09546634.2020.1799918"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e237367","DOI":"10.1136\/bcr-2020-237367","article-title":"Guttate psoriasis secondary to COVID-19","volume":"13","author":"Gananandan","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_14","first-page":"1","article-title":"COVID-19 infection cause moderate-severe psoriasis flare up","volume":"2","year":"2020","journal-title":"Eur. J. Med. Health Sci."},{"key":"ref_15","first-page":"e14595","article-title":"Generalized pustular psoriasis following COVID-19","volume":"34","author":"Dadras","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e14462","DOI":"10.1111\/dth.14462","article-title":"Pustular psoriasis exacerbated by COVID-19 in a patient with the history of psoriasis","volume":"33","author":"Shakoei","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1111\/jocd.14396","article-title":"Guttate flare in a patient with chronic plaque psoriasis following COVID-19 infection: A case report","volume":"20","author":"Agarwal","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1111\/jocd.14508","article-title":"Pustular psoriasis flare-up in a patient with COVID-19","volume":"20","author":"Miladi","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/BTT.S302164","article-title":"Acrodermatitis continua of Hallopeau evolving into generalized pustular psoriasis following COVID-19: A case report of a successful treatment with infliximab in combination with acitretin","volume":"15","author":"Samotij","year":"2021","journal-title":"Biol. Targets Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jdcr.2020.10.013","article-title":"New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019","volume":"6","author":"Mathieu","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e04542","DOI":"10.1002\/ccr3.4542","article-title":"New-onset guttate psoriasis secondary to COVID-19","volume":"9","author":"Rouai","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mroz, M., Mu\u0107ka, S., Miodo\u0144ska, M., Ziolkowska, D., Hadas, E., and Bo\u017cek, A. (2021). Influence of SARS-CoV-2 virus infection on the course of psoriasis during treatment with biological drugs. Medicina, 57.","DOI":"10.3390\/medicina57090881"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1111\/jocd.14381","article-title":"Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course","volume":"20","author":"Tabak","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e13805","DOI":"10.1111\/dth.13805","article-title":"COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy","volume":"33","author":"Filippi","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kartal, S.P., \u00c7elik, G., Y\u0131lmaz, O., Solak, E., G\u00fcl, B.D., \u00dcst\u00fcnba\u015f, T.K., G\u00f6n\u00fclal, M., Baysak, S., Y\u00fcksel, E.I., and \u00dcnl\u00fc, B. (2021). The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: A cross-sectional multicenter study from Turkey. J. Dermatol. Treat., 1\u20138.","DOI":"10.1080\/09546634.2021.1927947"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pirro, F., Caldarola, G., Chiricozzi, A., Tambone, S., Mariani, M., Calabrese, L., D\u2019Urso, D.F., De Simone, C., and Peris, K. (2020). The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies. J. Dermatol. Treat., 1\u20135.","DOI":"10.1080\/09546634.2020.1800578"},{"key":"ref_27","first-page":"e14691","article-title":"The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul","volume":"34","author":"Polat","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1684\/ejd.2020.3960","article-title":"A survey of psoriasis patients on biologics during COVID-19: A high-epidemic area experience\u2014Franche Comt\u00e9, France","volume":"31","author":"Puzenat","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_29","first-page":"1471","article-title":"A survey of psoriasis patients on biologics during COVID-19: A single centre experience","volume":"1","author":"Burlando","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e636","DOI":"10.1111\/jdv.17450","article-title":"Describing the burden of the COVID-19 pandemic in people with psoriasis: Findings from a global cross-sectional study","volume":"35","author":"Mahil","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Aram, K., Patil, A., Goldust, M., and Rajabi, F. (2021). COVID-19 and exacerbation of dermatological diseases: A review of the available literature. Dermatol. Ther., e15113.","DOI":"10.1111\/dth.15113"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2020-4-10","article-title":"Psoriasis, biologic therapy, and the pandemic of the 21st century","volume":"9","author":"Nogueira","year":"2020","journal-title":"Drugs Context"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e13467","DOI":"10.1111\/dth.13467","article-title":"Biologics for psoriasis in COVID-19 era: What do we know?","volume":"33","author":"Megna","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1684\/ejd.2021.4016","article-title":"Psoriasis care during the time of COVID-19: Real-world data on changes in treatments and appointments from a German university hospital","volume":"31","author":"Ninosu","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jaad.2020.07.021","article-title":"Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study","volume":"83","author":"Georgakopoulos","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jaad.2020.04.165","article-title":"COVID-19 and biologics for psoriasis: A high-epidemic area experience\u2014Bergamo, Lombardy, Italy","volume":"83","author":"Carugno","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e770","DOI":"10.1111\/jdv.16841","article-title":"Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy","volume":"34","author":"Talamonti","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1111\/jdv.16771","article-title":"Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: A multicenter study in the Czech Republic","volume":"34","author":"Rob","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e13508","DOI":"10.1111\/dth.13508","article-title":"COVID-19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED-ZONE declaration","volume":"33","author":"Bragazzi","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2147\/PPA.S263843","article-title":"Nonadherence to treatment and patient-reported outcomes of psoriasis during the COVID-19 epidemic: A web-based survey","volume":"14","author":"Wang","year":"2020","journal-title":"Patient Prefer. Adherence"},{"key":"ref_41","first-page":"e14700","article-title":"Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience","volume":"34","author":"Ekinci","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_42","first-page":"e249","article-title":"Understanding views of patients on biologics for psoriasis amid the COVID-19 pandemic","volume":"35","author":"Pandher","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S2665-9913(20)30390-8","article-title":"Hydroxychloroquine in the prevention of COVID-19 mortality","volume":"3","author":"Jorge","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jaad.2020.05.074","article-title":"Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment","volume":"83","author":"Sachdeva","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-4362.1999.00574.x","article-title":"The in vitro effect of hydroxychloroquine on skin morphology in psoriasis","volume":"38","author":"Wolf","year":"1999","journal-title":"Int. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.4049\/jimmunol.1303276","article-title":"Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells","volume":"193","author":"Said","year":"2014","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2230.2005.01910.x","article-title":"Precipitation of generalized pustular psoriasis by prednisolone","volume":"31","author":"Elston","year":"2006","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_48","first-page":"e5099","article-title":"An uncommon presentation of erythrodermic psoriasis in a patient without a history of psoriasis","volume":"11","author":"Rendo","year":"2019","journal-title":"Cureus"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/ijd.13956","article-title":"The associations between psychological stress and psoriasis: A systematic review","volume":"57","author":"Stewart","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2020.05.018","article-title":"Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: A web-based survey","volume":"83","author":"Kuang","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1111\/ijd.14785","article-title":"Zika, chikungunya, and dengue infections as exacerbating factors of psoriasis in patients receiving biological therapy","volume":"59","author":"Araujo","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/bjd.18203","article-title":"Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds","volume":"181","author":"Sbidian","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3389\/fimmu.2020.01518","article-title":"Targeting the NLRP3 inflammasome in severe COVID-19","volume":"11","author":"Freeman","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e2114531","DOI":"10.1001\/jamanetworkopen.2021.14531","article-title":"Comparison of COVID-19 vaccine approvals at the US Food and drug administration, European medicines agency, and health Canada","volume":"4","author":"Lythgoe","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s13555-021-00610-z","article-title":"Vaccines against SARS-CoV-2 in psoriasis patients on immunosuppressive therapy: Implications of vaccination nationwide campaign on clinical practice in Italy","volume":"11","author":"Diotallevi","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1203475421991126","article-title":"A psoriatic patient-based survey on the understanding of the use of vaccines while on biologics during the COVID-19 pandemic","volume":"25","author":"Le","year":"2021","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bjd.19882","article-title":"COVID-19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision","volume":"185","author":"Sotiriou","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e857","DOI":"10.1111\/jdv.17582","article-title":"Psoriasis exacerbation after COVID-19 vaccination: A report of 14 cases from a single centre","volume":"35","author":"Sotiriou","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_60","first-page":"e632","article-title":"Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine","volume":"35","author":"Krajewski","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2021.08.035","article-title":"Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine","volume":"17","author":"Perna","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"261","DOI":"10.34172\/hpp.2021.32","article-title":"A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report","volume":"11","author":"Onsun","year":"2021","journal-title":"Health Promot. Perspect."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e15110","DOI":"10.1111\/dth.15110","article-title":"Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases","volume":"34","author":"Bostan","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e15085","DOI":"10.1111\/dth.15085","article-title":"Onset\/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca\/Covishield): Report of two cases","volume":"34","author":"Nagrani","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1111\/1346-8138.16137","article-title":"Psoriasis exacerbation after first dose of AstraZeneca coronavirus disease 2019 vaccine","volume":"48","author":"Fang","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Pesqu\u00e9, D., Lopez-Trujillo, E., Marcantonio, O., Gim\u00e9nez-Arnau, A.M., and Pujol, R.M. (2021). New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: Two sides of the same coin?. J. Eur. Acad. Dermatol. Venereol.","DOI":"10.1111\/jdv.17690"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e15055","DOI":"10.1111\/dth.15055","article-title":"Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor","volume":"34","author":"Mieczkowska","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Elamin, S., Hinds, F., and Tolland, J. (2021). De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine. Clin. Exp. Dermatol.","DOI":"10.1111\/ced.14895"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1111\/jdv.17561","article-title":"New onset of mainly guttate psoriasis after COVID-19 vaccination: A case report","volume":"35","author":"Lehmann","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Watad, A., De Marco, G., Mahajna, H., Druyan, A., Eltity, M., Hijazi, N., Haddad, A., Elias, M., Zisman, D., and Naffaa, M. (2021). Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination. Vaccines, 9.","DOI":"10.3390\/vaccines9050435"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Skroza, N., Bernardini, N., Tolino, E., Proietti, I., Mambrin, A., Marchesiello, A., Marraffa, F., Rossi, G., Volpe, S., and Potenza, C. (2021). Safety and impact of anti-COVID-19 vaccines in psoriatic patients treated with biologics: A real life experience. J. Clin. Med., 10.","DOI":"10.3390\/jcm10153355"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/ced.14631","article-title":"COVID-19 vaccination and patients with psoriasis under biologics: Real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers","volume":"46","author":"Damiani","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Megna, M., Potestio, L., Gallo, L., Caiazzo, G., Ruggiero, A., and Fabbrocini, G. (2021). Reply to \u201cPsoriasis exacerbation after COVID-19 vaccination: Report of 14 cases from a single centre\u201d by Sotiriou, E.; et al. J. Eur. Acad. Dermatol. Venereol.","DOI":"10.1111\/jdv.17665"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Musumeci, M.L., Caruso, G., Trecarichi, A.C., and Micali, G. (2021). Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience. Dermatol. Ther., e15177.","DOI":"10.1111\/dth.15177"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/14712598.2021.1965985","article-title":"Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents","volume":"21","author":"Talamonti","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(21)01543-9","article-title":"CoronaVac: More data for regulators and policy makers","volume":"398","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e14011","DOI":"10.1111\/dth.14011","article-title":"Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: Is there a role for interleukin 17?","volume":"33","author":"Carugno","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Rosi, E., Fastame, M.T., Scandagli, I., Di Cesare, A., Ricceri, F., Pimpinelli, N., and Prignano, F. (2021). Insights into the pathogenesis of HS and therapeutical approaches. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091168"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/j.jaad.2020.05.012","article-title":"Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativa","volume":"83","author":"Seltzer","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5556354","DOI":"10.1155\/2021\/5556354","article-title":"NAFLD and infection, a nuanced relationship","volume":"2021","author":"Adenote","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1684\/ejd.2020.3927","article-title":"Hidradenitis suppurativa and adalimumab in the COVID-19 era","volume":"30","author":"Marzano","year":"2020","journal-title":"Eur. J. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e14256","DOI":"10.1111\/dth.14256","article-title":"Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy","volume":"33","author":"Molinelli","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e13680","DOI":"10.1111\/dth.13680","article-title":"Moderate-to-severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak","volume":"33","author":"Rozzo","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Marasca, C., Ruggiero, A., Megna, M., Annunziata, M.C., and Fabbrocini, G. (2020). Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: Data from a referral center of Southern Italy. J. Dermatol. Treat., 1.","DOI":"10.1080\/09546634.2020.1769828"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/j.jaad.2020.06.986","article-title":"Experience in patients with hidradenitis suppurativa and COVID-19 symptoms","volume":"83","author":"Silvente","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bjd.19492","article-title":"COVID-19 in patients with hidradenitis suppurativa","volume":"184","author":"Lima","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/exd.14339","article-title":"Anti-COVID-19 measurements for hidradenitis suppurativa patients","volume":"30","author":"Bettoli","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jaad.2020.06.1016","article-title":"The spectrum of COVID-19\u2013associated dermatologic manifestations: An international registry of 716 patients from 31 countries","volume":"83","author":"Freeman","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_89","first-page":"e13875","article-title":"Management of patients with hidradenitis suppurativa during the COVID-19 pandemic","volume":"33","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"109853","DOI":"10.1016\/j.mehy.2020.109853","article-title":"May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?","volume":"143","author":"Marasca","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"345","DOI":"10.23736\/S0391-1977.20.03248-4","article-title":"Endocrinological disorders and inflammatory skin diseases during COVID-19 outbreak: A review of the literature","volume":"45","author":"Marasca","year":"2021","journal-title":"Minerva Endocrinol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Rosi, E., Pimpinelli, N., and Prignano, F. (2020). Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?. J. Dermatol. Treat., 1.","DOI":"10.1080\/09546634.2020.1771256"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5070\/D3272052396","article-title":"Hidradenitis suppurativa patient perspectives during the COVID-19 pandemic","volume":"27","author":"Price","year":"2021","journal-title":"Dermatol. Online J."},{"key":"ref_94","first-page":"616","article-title":"May COVID-19 infection induce a paradoxical improvement of a non-responsive case of hidradenitis suppurativa?","volume":"156","author":"Caro","year":"2021","journal-title":"Ital. J. Dermatol. Venereol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/24\/5841\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:46:48Z","timestamp":1760168808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/24\/5841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":94,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["jcm10245841"],"URL":"https:\/\/doi.org\/10.3390\/jcm10245841","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2021,12,13]]}}}